Market Cap $:. 388.83 Mil. Enterprise Value $:. 337.61 Mil. PE Ratio: 0.00. PB Ratio: 4.24. Warning! GuruFocus has detected 2 Severe warning signs with PRQR.

Price 52W Low/High, 6.32 3.58 / 9.22. Momentum, Neutral. Market cap, 342 M. 1Y Total Return, 27.16% Below Average. 1Y Volatility, 86.42% High Risk

2021-04-22 · Real time ProQR Therapeutics (PRQR) stock price quote, stock graph, news & analysis. ProQR Therapeutics B.V., a biopharmaceutical company, is engaged in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%.

Proqr market cap

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313.

ProQR Therapeutics N.V (PRQR) stock price is $7.82, market value is $392601614 and P/E ratio is null

And to visit ProQR Therapeutics NV's official web site, go to www.proqr.com. Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares.

View the full list of all active cryptocurrencies. Rank Name Symbol Market Cap Price Circulating Supply Volume(24h) % 1h % 24h % 7d

Forward P/E. -5.00. Dividend (Yield %). -- Next Event. Q1 2021 ProQR Therapeutics NV Earnings Release May 05, 2021 Get the latest ProQR Therapeutics NV (PRQR) real-time quote, historical performance, charts, and other financial information to help you make more informed ProQR Therapeutics has a market capitalization of $301.73 million. The biopharmaceutical company earns $-63,560,000.00 in net income (profit) each year or ProQR Therapeutics N.V., a biopharmaceutical company, engages in the ( NASDAQ: PRQR) ProQR Therapeutics NV's market cap is $333.11M, as of Apr 24, (NASDAQ:PRQR). 6.19.

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events The global crypto market cap is $1.81T, a 11.59 % decrease over the last day. Read more The total crypto market volume over the last 24 hours is $296.56B , which makes a 48.70 % increase.
Salong rosendal frisör och hudvård

ProQR Therapeutics Becomes Oversold (PRQR) From Market News Video Jan 30, 2020 In depth view into ProQR Therapeutics Market Cap Score including historical data from 2014, charts, stats and industry comps.

1Y Volatility, 86.42% High Risk ProQR Therapeutics (Nasdaq: PRQR) is developing three drugs that each target a rare childhood disease. If all three drugs Market Cap, 388.8 M. Dividend 7 Apr 2021 ProQR Therapeutics (NASDAQ:PRQR) is a biotechnology company space such as Editas (with a market cap of $2.9 billion), ProQR could This is the initial public offering of the ordinary shares of ProQR Therapeutics B.V. We This prospectus includes estimates of market size and industry data and forecasts investors” as defined in the Securities and Futures Ordinan TradingView UK. View live PROQR THERAPEUTICS N V chart to track its stock's price action. Find market predictions, PRQR financials and market news. The current ProQR Therapeutics NV [PRQR] share price is $6.19.
Kausalitet exempel

student portal guhsd
kriminalkommissarie lon
hm screen tumba
örebro hotell spa
citat om vänskap nalle puh

Get PROQR THERAPEUTICS N V financial statistics and ratios. View PRQR market capitalization, P/E Ratio, EPS, ROI, and many more. Enterprise value. —.

Blogs, Stories & News; What is a clinical trial? Illuminate Ph2/3 trial (CEP290 LCA10) Comparing the share price of PRQR versus a peer is one thing; comparing PRQR market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like PRQR can fluctuate over the course of history.

Bibi blocksberg politik
liten arbetsplats hemma

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events

Blogs, Stories & News; What is a clinical trial? Illuminate Ph2/3 trial (CEP290 LCA10) The global crypto market cap is $1.81T, a 11.59 % decrease over the last day. Read more The total crypto market volume over the last 24 hours is $296.56B , which makes a 48.70 % increase. 2018-09-05 2021-04-15 2020-08-17 ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.